Cetuximab

Pre-clinicalWithdrawn

1 views this week 0 watching💤 Quiet

Interest: 18/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neoplasms, Squamous Cell

Conditions

Neoplasms, Squamous Cell

Trial Timeline

Mar 1, 2009 → —

NCT ID

NCT01075841

About Cetuximab

Cetuximab is a pre-clinical stage product being developed by Merck for Neoplasms, Squamous Cell. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01075841. Target conditions include Neoplasms, Squamous Cell.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasms, Squamous Cell were approved

Approved (20) Terminated (2) Active (0)

✅LenvatinibEisaiApproved

✅Eribulin mesylateEisaiApproved

✅Eribulin MesylateEisaiApproved

✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved

✅Chlorhydrate de RopivacaineAstraZenecaApproved

✅Sitagliptin + placeboMerckApproved

✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03524820	Phase 2	Terminated	Oct 17, 2017	Dec 31, 2021	Cancer of Colon
NCT01192087	Phase 1/2	UNKNOWN	Jun 1, 2012	Jul 1, 2017	Adenoid Cystic Carcinoma
NCT01450319	Phase 2	Completed	Dec 1, 2011	Dec 1, 2014	Colorectal Neoplasms
NCT01382407	Pre-clinical	Completed	Jul 1, 2011	Apr 1, 2017	Colorectal Cancer Metastatic
NCT01230476	Phase 2	Terminated	May 1, 2010	May 1, 2015	Nasopharyngeal Carcinoma
NCT01142869	Pre-clinical	Terminated	Dec 31, 2009	Aug 5, 2014	Carcinoma, Squamous Cell
NCT01134666	Pre-clinical	Terminated	Nov 30, 2009	Aug 5, 2014	Colorectal Neoplasms
NCT01075841	Pre-clinical	Withdrawn	Mar 1, 2009	—	Neoplasms, Squamous Cell
NCT00865098	Phase 2	Completed	Mar 1, 2009	Jun 1, 2010	Carcinoma of the Head and Neck
NCT00827671	Phase 2	Terminated	Mar 1, 2009	Mar 1, 2016	Resectable Esophageal Cancer
NCT01075828	Pre-clinical	Completed	Mar 1, 2009	Jul 1, 2014	Head and Neck Cancer
NCT01074333	Pre-clinical	Terminated	Sep 1, 2008	Jan 1, 2012	Colorectal Neoplasm
NCT00714649	Phase 1/2	Completed	Jul 1, 2008	May 1, 2011	Head and Neck Cancer
NCT00522886	Phase 1	Completed	Apr 1, 2007	—	Non-small Cell Lung Cancer
NCT00251381	Phase 2	UNKNOWN	Nov 1, 2005	Nov 1, 2009	Oropharyngeal Neoplasms

Competing Products

20 competing products in Neoplasms, Squamous Cell

See all competitors

Product	Company	Stage	Hype Score
ADC-1013	Alligator Bioscience AB	Phase 1	19
AB0024	Gilead Sciences	Phase 1	29
TTI-237	Pfizer	Phase 1	21
852A	Pfizer	Phase 1	29
Pemetrexed	Eli Lilly	Phase 2	35
IMC-3C5	Eli Lilly	Phase 1	29
LY3295668	Eli Lilly	Phase 1/2	32
Galunisertib + Gemcitabine + Placebo	Eli Lilly	Phase 1/2	32
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	39
Abemaciclib + Fulvestrant + Placebo	Eli Lilly	Phase 3	44
LY2784544	Eli Lilly	Phase 1	29
enzastaurin	Eli Lilly	Phase 2	35
Abemaciclib + Darolutamide + LHRH agonist/antagonist	Eli Lilly	Phase 1	29
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	40
120 mg LY2784544	Eli Lilly	Phase 2	39
LY4337713	Eli Lilly	Phase 1	36
pemetrexed + cisplatin	Eli Lilly	Phase 1/2	32
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant	Eli Lilly	Phase 3	47
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg	Vincerx Pharma	Phase 1	19
VIP236 (Q3W) + VIP236 (Q2W)	Vincerx Pharma	Phase 1	19